Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring SHR117887, Metformin,combination,PhaseII
Eligibility Criteria
Inclusion Criteria:
- Patients diagnosed with type 2 diabetes mellitus
- Patients have been treated with metformin for at least 8 weeks and be on a stable dose of at least 1500mg daily prior to the screening visit
- HbA1C:≥7.5% and ≤11.0% at screeing visit and at the end of run-in period
- Age:≥20 and ≤70 years
- BMI(body mass index):≥20 and ≤35 kg/m2
Exclusion Criteria:
-
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Experimental
Experimental
Placebo/Metformin
SHR117887 (50mg q.d)/Metformin
SHR117887 (100mg q.d)/Metformin
patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.